Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 6;8(24):21745-21754.
doi: 10.1021/acsomega.3c01287. eCollection 2023 Jun 20.

Immunomagnetic Isolation of HER2-Positive Breast Cancer Cells Using a Microfluidic Device

Affiliations

Immunomagnetic Isolation of HER2-Positive Breast Cancer Cells Using a Microfluidic Device

Delaram Parvin et al. ACS Omega. .

Abstract

Analysis of circulating tumor cells (CTCs) as a tool for monitoring metastatic cancers, early diagnosis, and evaluation of disease prognosis paves the way toward personalized cancer treatment. Developing an effective, feasible, and low-cost method to facilitate CTC isolation is, therefore, vital. In the present study, we integrated magnetic nanoparticles (MNPs) with microfluidics and used them for the isolation of HER2-positive breast cancer cells. Iron oxide MNPs were synthesized and functionalized with the anti-HER2 antibody. The chemical conjugation was verified by Fourier transform infrared spectroscopy, energy-dispersive X-ray spectroscopy, and dynamic light scattering/zeta potential analysis. The specificity of the functionalized NPs for the separation of HER2-positive from HER2-negative cells was demonstrated in an off-chip test setting. The off-chip isolation efficiency was 59.38%. The efficiency of SK-BR-3 cell isolation using a microfluidic chip with a S-shaped microchannel was considerably enhanced to 96% (a flow rate of 0.5 mL/h) without chip clogging. Besides, the analysis time for the on-chip cell separation was 50% faster. The clear advantages of the present microfluidic system offer a competitive solution in clinical applications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
MNPs’ surface modification by HER2 investigated through (A) FTIR, (B) DLS/zeta potential analysis, and (C) EDS analysis.
Figure 2
Figure 2
Representative fluorescent microscopy images of off-chip cell isolation, (A) SKBR3 cells stained with DAPI, (B,C) stained SKBR3 cells incubated with HER2-MNPs before and after magnetic washing, (D) MDA-MB-231 cells stained with fluorescein dye, (E,F) stained MDA-MB-231 cells incubated with HER2-MNPs before and after magnetic washing, (G–I) blue, green, and merged fluorescent images of stained SKBR3 and MDA-MB-231 cell cocktail incubated with HER2-MNPs before magnetic washing, (J–L) blue, green, and merged fluorescent images of stained SKBR3 and MDA-MB-231 cell cocktail incubated with HER2-MNPs after magnetic washing, aand (M,N) stained SKBR3 cells incubated with bare MNPs before and after magnetic washing.
Figure 3
Figure 3
Capture efficiency of the off-chip isolation by flow cytometry. Forward and side scatter density plots of (A) 5 × 105 unstained SK-BR-3, (B) 5 × 105 unstained MDA-MB-231, (C) 2.5 × 105 unstained SK-BR-3 mixed with 2.5 × 105 unstained MDA-MB-231, (D) the overlay of (A–C), the fluorescein signal of (E) 5 × 105 unstained SK-BR-3, (F) 5 × 105 stained SK-BR-3, 2.5 × 105 stained SK-BR-3 + 2.5 × 105 unstained MDA-MB-231 incubated with (G) HER2-MNPs, (H) bare MNPs, and (I) HER2.
Figure 4
Figure 4
Fluorescence microscopy images of on-chip cell isolation, (A,B) movement of stained SK-BR-3 cells and HER2-MNPs inside the chip, (C) magnetic enrichment of the cells attached to the HER2-MNPs in the trap region, (D) high magnification of fluorescent SK-BR-3 cells in the trap region, (E) fluorescence and bright-field images of SK-BR-3 cells separated after magnetic washing, and (F) SK-BR-3 cell isolation efficiency versus fluid’s flow rate inside the chip (the green bar shows the optimum flow rate value).

Similar articles

Cited by

References

    1. Ruddon R. W.Characteristics of Human Cancer. Cancer Biology; Oxford University Press, 2007; pp 3–15.
    1. Jemal A.; Siegel R.; Xu J.; Ward E. Cancer Statistics, 2010. Ca-Cancer J. Clin. 2010, 60, 277–300. 10.3322/caac.20073. - DOI - PubMed
    1. Miller K. D.; Nogueira L.; Mariotto A. B.; Rowland J. H.; Yabroff K. R.; Alfano C. M.; Jemal A.; Kramer J. L.; Siegel R. L. Cancer Treatment and Survivorship Statistics, 2019. Ca-Cancer J. Clin. 2019, 69, 363–385. 10.3322/caac.21565. - DOI - PubMed
    1. Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D. M.; Forman D.; Bray F. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. 10.1002/ijc.29210. - DOI - PubMed
    1. Alix-Panabières C.; Pantel K. Circulating Tumor Cells: Liquid Biopsy of Cancer. Clin. Chem. 2013, 59, 110–118. 10.1373/clinchem.2012.194258. - DOI - PubMed